Peer Review File

Article Information: https://dx.doi.org/10.21037/tlcr-23-838

Reviewer A

Comment 1: The authors adequately summarized the report by Paweletz et al. published in Clinical Cancer Research in 2023. I have no critique on this Editorial Commentary.

Reply 1: We thank the reviewer for the comment
Changes in the text: not applicable

Reviewer B

Comment 1: The authors write a clear and informative editorial on early clearance of plasma circulating tumor DNA in Patients with advanced KRAS G12C Mutant Non-Small Cell Lung Cancer.
Specific points checked:
Conclusions clear, meaningful and well done
Figure informative overview on the study commented on
Language, style: well done
Literature: appropriately cited and interesting references
Moreover, the contents was a pleasure to read

Reply 1: We thank the reviewer for their kind comment
Changes in the text: not applicable

Reviewer C

Comment 1: This is a nicely written commentary. The authors could optionally also cite additional similar studies, like the ctDNA assessment of response in the CROWN study (https://www.jto.org/article/S1556-0864(23)00580-4/fulltext) and also the fact that serial ctDNA assays can also detect progression earlier than radiologic imaging (e.g., https://www.nature.com/articles/s41698-021-00239-3)

Reply 1: We thank the reviewer for the comment. We have added both references
Changes in the text: We deleted reference 4 (Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015 Feb;4(1):36–54) and 22 (Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, et al. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl Lung Cancer Res. 2020 Apr;9(2):269–79) to make room for these two referents which are more recent, since the limit is 25 references.